This trial is active, not recruiting.

Condition cardiac sarcoidosis
Treatment 11c-pbr pet
Phase phase 0
Sponsor University of Michigan
Start date December 2013
End date January 2017
Trial size 8 participants
Trial identifier NCT02017522, HUM00079881


In a study of Cardiac sarcoidosis, a serious heart condition, a radiotracer is being used to examine inflammation.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Intervention model single group assignment
Masking open label
Primary purpose basic science
Subjects will have a blood sample drawn to evaluate the presence of a specific genetic variation which would prevent the new type of imaging test we are evaluating from working and we will test the inflammatory cells in the blood for the same purpose. All participants who proceed will have to return on at least one additional day to undergo a positron emission tomography (PET) scan similar to the scan your doctor ordered. we will use 11C-PBR28 as the radiotracer. This study will evaluate whether 11C-PBR28 can show areas of inflammation due to cardiac sarcoidosis. On either the same day or a different day, you will also undergo a cardiac MRI.
11c-pbr pet
Subjects will have a positron emission tomography (PET) CT scan using 11C-PBR28 as a radiotracer. This study will evaluate inflammation due to cardiac sarcoidosis. The CT scan will improve the images. The total scan time will be about 30 minutes. There will also be some time required for prep, such as inserting an intravenous (IV) catheter in an arm or forearm. Including prep time, the scan will take approximately two hours. Subjects will also undergo a cardiac MRI. Cardiac MRI uses strong magnetic fields to make pictures of the heart. We will use gadolinium containing contrast material, given through an intravenous (IV) catheter to highlight areas of scar in your heart which may be due to cardiac sarcoidosis. This scan will take about 60 minutes.

Primary Outcomes

Ratio of 11C-PBR28 in the myocardium
time frame: 3 years

Secondary Outcomes

The ratio of 11C-PBR28 PET activity in cardiac regions with fibrosis
time frame: 3 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: 1. 18 years of age or older 2. must have undergone a cardiac positron emission tomography (PET) scan using 18F-fluorodeoxyglucose (FDG) for clinical reasons (i.e. referred by your doctor) within the preceding 30 days which showed evidence of active inflammation in your heart. Exclusion Criteria: 1. If you have two copies of a genetic variation called rs6971 which will prevent this tracer from generating high-quality images you may not participate. If you consent, a blood sample will be drawn to check whether you have this genetic variation. 2. Pregnancy or breastfeeding. If you are female and still experience menstrual periods, you must be willing to use contraception until your participation in the study is complete. 3. Allergy or intolerance to contrast dye containing gadolinium 4. Claustrophobia which would prevent you from completing an approximately one hour MRI scan 5. Inability to lie flat with your arms by your head 6. Abnormal kidney function (estimated GFR(glomerular filtration rate) <60 ml/min/1.73 m2) 7. Implanted pacemaker, defibrillator or other medical devices which are not safe for 3 Tesla MRI 8. Metal in the eyes or shrapnel in the body 9. If you are clinically unstable you may not participate in this study. For example, if you have potentially life threatening abnormal heart rhythms which are not controlled by medication or other treatments, you cannot participate. Also, if you need medications to increase your blood pressure or cardiac function due to weak heart muscle, you cannot participate.

Additional Information

Official title Non-Invasive Characterization in Cardiac Sarcoidosis
Principal investigator Venkatesh L. Murthy, M.D.
Description Cardiac sarcoidosis is a serious medical condition which affects the heart. The purpose of this study is to characterize the relationship between the FDG PET findings and other markers of inflammation including using a new targeted PET radiotracer, 11C-PBR28, and analysis of blood specimens.
Trial information was received from ClinicalTrials.gov and was last updated in May 2016.
Information provided to ClinicalTrials.gov by University of Michigan.